Stifel Financial Corp (NYSE:SF). has announced a revision to its executive compensation structure, according to a recent SEC filing. On Monday, the Compensation Committee of the Board of Directors ...

Stifel Nicolaus analyst Matthew Smith, CFA maintained a Buy rating on Post Holdings (POST – Research Report) today and set a price target of ...

Eagle Financial Services, Inc. (OTCQX: EFSI) (the "Company"), parent company of Bank of Clarke, today announced the pricing of its previously announced underwritten public offering of 1,562,500 shares ...

Apple supplier Skyworks Solutions saw its stock drop nearly 25% Thursday as the semiconductor firm said that it's losing ...

Fintel reports that on February 5, 2025, Stifel upgraded their outlook for Hayward Holdings (NYSE:HAYW) from Hold to Buy.

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

Michael Boyle is an experienced financial professional with more than 10 years working with financial planning, derivatives, equities, fixed income, project management, and analytics. Sarinya ...

Stifel's focus on self-help and growth opportunities suggests that while the overall sector outlook is cautious, there may still be potential for strategic investment moves within the industry.

Comment: New Zealand stood uncertainly at multiple economic and social crossroads at the end of 2024. The hope was that a long, hot summer break would induce people to face 2025 with more confidence.

Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with ...

Shares of Edgewise Therapeutics (NASDAQ:EWTX) traded flat on Wednesday after Stifel launched its coverage with a Hold recommendation, indicating a balanced risk-reward profile for the muscle drug ...